BioCentury
ARTICLE | Top Story

Chiron's FGF-2 misses target

March 13, 2000 8:00 AM UTC

CHIR said its Phase II trial of recombinant fibroblast growth factor-2 in coronary artery disease did not meet its primary end point of increasing exercise capacity at 90 days, as measured by an exercise tolerance test. The FIRST ( FGF-2 Initiating Revascularization Support Trial) study enrolled 337 symptomatic CAD patients who were not suitable for angioplasty or bypass surgery. The company said the end points also will be assessed at 180 days, and noted that positive trends were seen in the secondary end point of reduction of angina frequency, as measured by both patient and physician. ...